首页> 美国卫生研究院文献>EBioMedicine >Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis
【2h】

Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis

机译:胶原蛋白特异性T细胞库和HLA-DR等位基因:活性难治性类风湿关节炎的生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rheumatoid arthritis (RA) is characterized by chronic joint inflammation and associates with HLA-DRB1*04. The Collagen IIp261-273-specific T cell repertoire in the peripheral blood of DR4 + patients at the onset of the disease shows a restricted TCR-beta chain usage among which the most frequent is TRBV25.To define whether this group of DR4-restricted collagen-specific shared T cell could represent markers of active-severe disease and response to therapy, 90 subjects affected by early-RA were enrolled in the study; peripheral blood mononuclear cells were cultured with or without the human collagen II peptide p261-273 and were examined by immunoscope analysis for the usage of the previously identified shared TCR-beta chains.We report that the presence of T cells carrying rearrangement TRBV25 associated with HLA-DR haplotype and disease activity. HLA-DRB1* haplotypes 04–04, 04–01 and 04–11 were significantly associated with usage of TRBV25, higher disease activity at the onset of disease and poor response to DMARDs.Finally, the HLA-DRB1* haplotype appeared complementary with current serologic tools to predict good and poor responders in a treat to target strategy. The data reported here offer clues to predict the course of the disease and to foresee personalized treatments in RA patients.
机译:类风湿关节炎(RA)的特征是慢性关节发炎,并与HLA-DRB1 * 04有关。疾病发作时DR4 +患者外周血中的胶原IIp261-273特异性T细胞库显示TCR-β链使用受限,其中最常见的是TRBV25。特异的共享T细胞可代表活动性重症疾病和对治疗的反应标记物,该研究招募了90名受早期RA影响的受试者。外周血单个核细胞在有或没有人胶原II肽p261-273的情况下进行培养,并通过免疫镜分析检查了先前鉴定的共享TCR-β链的用途。我们报道存在携带重排TRBV25的T细胞与HLA相关-DR单倍型和疾病活性。 HLA-DRB1 *单倍型04–04、04–01和04-11与TRBV25的使用,发病时较高的疾病活动性和对DMARD的不良反应密切相关。最后,HLA-DRB1 *单倍型似乎与目前的互补血清学工具可预测目标策略中治疗效果的好坏。本文报道的数据为预测RA的病程和预见个性化治疗提供了线索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号